Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system (CNS) diseases. The company was established in 2018 as a spinout from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts.

Cyclerion’s primary research program was CY6463, an oral, CNS-penetrant soluble guanylate cyclase stimulator designed to influence biological pathways associated with neurodegenerative and mitochondrial diseases. The company evaluated CY6463 in clinical studies involving conditions such as Alzheimer’s disease and mitochondrial encephalomyopathy. Its earlier pipeline also included CY3018, another soluble guanylate cyclase stimulator investigated for potential use in sickle cell disease.

The company’s activities were centered on pharmaceutical research and clinical development rather than commercial product sales. Its programs were developed for potential use in global markets, although Cyclerion did not have an established portfolio of marketed medicines. Available public information primarily describes the company during its period as an independent clinical-stage biotechnology business.

Key Stats

• Today's Range: N/A
• 50-Day Range: $3.49 to $34.72
• 52-Week Range: N/A
• Volume: 435,914 shs
• Average Volume: 96,117 shs
• Market Capitalization: $16.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Cyclerion Therapeutics Stock Analysis - MarketRank™

Cyclerion Therapeutics scored higher than 19% of companies evaluated by MarketBeat, and ranked 804th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Cyclerion Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cyclerion Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cyclerion Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclerion Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclerion Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.59% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently decreased by 65.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclerion Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclerion Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CYCN
• CIK: 1755237
• Web: www.cyclerion.com
• Phone: (857) 327-8778
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.53 million
• Net Margins: -170.11%
• Pretax Margin: -353.00%
• Return on Equity: -87.96%
• Return on Assets: -74.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.31 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,680,000
• Free Float: 3,075,000
• Market Cap: $16.33 million
• Optionable: No Data
• Beta: 1.75